Managing thrombotic risk in myeloproliferative disorders.

Authors

Gerard Gurumurthy, Minji Ho, Jecko Thachil, Priya Sriskandarajah

Published in

Expert review of hematology. Sep 11, 2026. Epub Sep 11, 2026.

Abstract

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders associated with arterial and venous thrombosis. Thrombotic risk reflects conventional vascular factors and disease-specific thromboinflammatory biology. Thrombosis remains a major cause of morbidity and mortality in MPNs despite contemporary guidelines. Thus, there remains a challenging therapeutic uncertainty across diverse clinical presentations.
We reviewed PubMed-listed articles on the epidemiology, mechanisms, risk stratification and clinical management of thrombosis in classical Philadelphia-negative MPNs. We discuss evidence for aspirin, hematocrit control, cytoreduction and anticoagulation choice. We also examine management in special populations such as in pregnancy and frailty. Lastly, we give an overview on the emerging use of Direct oral anticoagulants (DOACs) in unusual site thrombosis in this setting.
Thrombosis in MPNs should not be treated as a single entity. Arterial, venous and unusual-site events all differ in biology and this can have therapeutic implications. Future progress requires personalized strategies that balance thrombosis prevention, bleeding risk and clonal disease control in a heterogenous group.

PMID:
42728032
Bibliographic data and abstract were imported from PubMed on 12 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.